Related Experiment Video
Updated: Apr 25, 2026
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
Ivabradine Versus Beta-Blockers in Patients with Conduction Abnormalities or Left Ventricular Dysfunction Undergoing
Luminita Iliuta1, Marius Rac-Albu2
1"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Insights
Combined ivabradine and metoprolol therapy effectively reduced heart rate and prevented arrhythmias post-cardiac surgery in patients with conduction abnormalities or LV dysfunction. This combination therapy demonstrated superior efficacy and safety compared to monotherapy.
Area of Science:
- Cardiology
- Cardiac Surgery
- Pharmacology
Background:
- Managing rhythm control post-cardiac surgery is challenging in patients with conduction abnormalities or left ventricle (LV) dysfunction.
- Limited data exists on the use of ivabradine in the postoperative cardiac surgery setting.
- This study addresses the need for effective and safe rhythm control strategies in this patient population.
Purpose of the Study:
- To compare the efficacy and safety of ivabradine versus metoprolol for perioperative rhythm control in cardiac surgery patients.
- To evaluate the effectiveness of combined ivabradine and metoprolol therapy.
- To assess outcomes in patients with conduction abnormalities or LV systolic dysfunction.
Main Methods:
- An open-label, randomized clinical trial involving 527 patients undergoing coronary artery bypass grafting or valvular replacement.
- Patients were randomized to receive ivabradine, metoprolol, or a combination of both.
- Primary endpoints included 30-day mortality, in-hospital atrial fibrillation, atrioventricular block, need for pacing, and worsening heart failure.
Main Results:
- Combined therapy (ivabradine + metoprolol) was more effective in heart rate reduction and preventing postoperative atrial fibrillation and tachyarrhythmia than monotherapy.
- The ivabradine group showed lower frequencies of early postoperative pacing and heart failure worsening compared to the metoprolol group.
- The primary composite endpoint was significantly lower in the combined therapy group versus monotherapy groups.
Conclusions:
- Perioperative combination therapy with ivabradine and metoprolol is the most effective treatment for cardiac rhythm reduction post-open heart surgery in patients with conduction abnormalities or LV dysfunction.
- This combined approach offers a favorable balance of efficacy and safety.
- The findings support the use of ivabradine in conjunction with metoprolol for improved outcomes in specific cardiac surgery patient groups.
Introduction:
In patients with conduction abnormalities or left ventricle (LV) dysfunction the use of β-blockers for post cardiac surgery rhythm control is difficult and controversial, with a paucity of information about other drugs such ivabradine used postoperatively. The objective of this study was to compare the efficacy and safety of ivabradine versus metoprolol used perioperatively in cardiac surgery patients with conduction abnormalities or LV systolic dysfunction.
Methods:
This was an open-label, randomized clinical trial enrolling 527 patients with conduction abnormalities or LV systolic dysfunction undergoing coronary artery bypass grafting or valvular replacement, randomized to take ivabradine or metoprolol, or metoprolol plus ivabradine. The primary endpoints were the composites of 30-day mortality, in-hospital atrial fibrillation (AF), in-hospital three-degree atrioventricular block and need for pacing, in-hospital worsening heart failure (HF; safety endpoints), duration of hospital stay and immobilization and the above endpoint plus in-hospital bradycardia, gastrointestinal symptoms, sleep disturbances, cold extremities (efficacy plus safety endpoint).
Results:
Heart rate reduction and prevention of postoperative AF or tachyarrhythmia with combined therapy was more effective than with metoprolol or ivabradine alone during the immediate postoperative management of cardiac surgery patients. In the Ivabradine group, the frequency of early postoperative pacing and HF worsening was smaller than in the Metoprolol group and in combined therapy group. The frequency of primary combined endpoint was lower in the combined Ivabradine + Metoprolol group compared with the monotherapy groups.
Conclusion:
Considering efficacy and safety, the cardiac rhythm reduction after open heart surgery in patients with conduction abnormalities or LV dysfunction with ivabradine plus metoprolol emerged as the best treatment in this trial.
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:22Heart Failure Drugs: β-Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers